Fulcrum Therapeutics (NASDAQ:FULC) Upgraded by Zacks Investment Research to Buy

Fulcrum Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Fulcrum Therapeutics Upgraded by Zacks Investment Research on 10/12/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

View More Fulcrum Therapeutics (NASDAQ:FULC) Upgraded by Zacks Investment Research to Buy